1. Home
  2. IMAB vs VIGL Comparison

IMAB vs VIGL Comparison

Compare IMAB & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • VIGL
  • Stock Information
  • Founded
  • IMAB 2014
  • VIGL 2020
  • Country
  • IMAB United States
  • VIGL United States
  • Employees
  • IMAB N/A
  • VIGL N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMAB Health Care
  • VIGL Health Care
  • Exchange
  • IMAB Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • IMAB 79.9M
  • VIGL 89.3M
  • IPO Year
  • IMAB 2020
  • VIGL 2022
  • Fundamental
  • Price
  • IMAB $0.97
  • VIGL $2.66
  • Analyst Decision
  • IMAB Strong Buy
  • VIGL Strong Buy
  • Analyst Count
  • IMAB 3
  • VIGL 5
  • Target Price
  • IMAB $8.00
  • VIGL $21.00
  • AVG Volume (30 Days)
  • IMAB 280.2K
  • VIGL 2.6M
  • Earning Date
  • IMAB 03-13-2025
  • VIGL 03-25-2025
  • Dividend Yield
  • IMAB N/A
  • VIGL N/A
  • EPS Growth
  • IMAB N/A
  • VIGL N/A
  • EPS
  • IMAB N/A
  • VIGL N/A
  • Revenue
  • IMAB $3,313,984.00
  • VIGL N/A
  • Revenue This Year
  • IMAB N/A
  • VIGL N/A
  • Revenue Next Year
  • IMAB N/A
  • VIGL N/A
  • P/E Ratio
  • IMAB N/A
  • VIGL N/A
  • Revenue Growth
  • IMAB N/A
  • VIGL N/A
  • 52 Week Low
  • IMAB $0.84
  • VIGL $1.49
  • 52 Week High
  • IMAB $2.00
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • VIGL 66.89
  • Support Level
  • IMAB $1.03
  • VIGL $2.53
  • Resistance Level
  • IMAB $1.10
  • VIGL $2.88
  • Average True Range (ATR)
  • IMAB 0.06
  • VIGL 0.30
  • MACD
  • IMAB -0.01
  • VIGL 0.06
  • Stochastic Oscillator
  • IMAB 7.58
  • VIGL 70.98

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: